Long-acting contraceptive agents: Norethisterone esters of arylcarboxylic acids
摘要:
The synthesis of esters of norethisterone (17 alpha-ethynyl-17 beta-hydroxy-estr-4-en-3-one) with acids containing a benzene ring is described, two methods of esterification being compared in terms of yield and convenience. The activities of these esters as long-acting contraceptive agents have been evaluated.
The present invention provides phenylalkylcarboxylic acid compounds and compositions containing such compounds which facilitate the delivery of biologically active agents.
本发明提供苯基烷基羧酸化合物及含有此类化合物的组合物,有助于传递生物活性物质。
Regio- and Enantioselective Catalytic δ-C–H Amidation of Dioxazolones Enabled by Open-Shell Copper-Nitrenoid Transfer
作者:Suhyeon Kim、Se Lin Song、Jianbo Zhang、Dongwook Kim、Sungwoo Hong、Sukbok Chang
DOI:10.1021/jacs.3c05258
日期:2023.7.26
>19:1 rr and >99:1 er). Combined experimental and computational mechanistic studies unveiled that the open-shell character of the postulated Cu-nitrenoids enables the regioselective hydrogen atom abstraction and subsequent enantio-determining radical rebound of the resulting carbon radical intermediates. The synthetic utility of this asymmetric cyclization was demonstrated in the diastereoselective introduction
The present invention provides phenylalkylcarboxylic acid compounds and compositions containing such compounds which facilitate the delivery of biologically active agents.
本发明提供了苯基烷基羧酸化合物和含有此类化合物的组合物,它们有助于生物活性剂的递送。
COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE
申请人:Urigen Pharmaceuticals, Inc.
公开号:EP3110427A1
公开(公告)日:2017-01-04
COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS
申请人:PARSONS C. Lowell
公开号:US20170189443A1
公开(公告)日:2017-07-06
The present invention is directed to a pharmaceutical composition comprising: (1) a therapeutically effective quantity of sodium pentosan polysulfate; (2) a quantity of a penetration enhancer sufficient to improve the bioavailability of the sodium pentosan polysulfate; and (3) optionally, a pharmaceutically acceptable carrier and to methods for the oral administration of sodium pentosan polysulfate with improved bioavailability for the treatment of interstitial cystitis and other urinary tract diseases and conditions. Such compositions and methods allow the administration of sodium pentosan polysulfate at lower dosages to reduce the frequency and severity of side effects.